Neumann Frank, Gattermann Norbert, Barthelmes Hans-Ulrich, Haas Rainer, Germing Ulrich
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany.
Leuk Res. 2009 Feb;33(2):232-6. doi: 10.1016/j.leukres.2008.06.003. Epub 2008 Jul 18.
We evaluated the relevance of beta 2 microglobulin (B2M) plasma concentration in 109 patients with myelodysplastic syndrome (MDS) from the Duesseldorf registry. Sixty-five patients with B2M level > or =2mg/dl showed a significantly lower overall survival time with a median of 23 in comparison to 61 months for 44 patients with B2M below 2mg/dl. The risk of AML evolution was higher in patients with B2M> or =2mg/dl. Using multivariate analysis we found the B2M level at the time of diagnosis to be an independent prognostic parameter for survival and for the risk of developing AML in high-risk MDS patients.
我们评估了来自杜塞尔多夫登记处的109例骨髓增生异常综合征（MDS）患者血浆β2微球蛋白（B2M）浓度的相关性。65例B2M水平≥2mg/dl的患者总生存时间显著缩短，中位数为23个月，而44例B2M低于2mg/dl的患者为61个月。B2M≥2mg/dl的患者发生急性髓系白血病（AML）演变的风险更高。通过多变量分析，我们发现诊断时的B2M水平是高危MDS患者生存及发生AML风险的独立预后参数。
